EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to folate and maintenance of normal blood pressure (ID 176) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 19, 2017
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to folate and maintenance of normal blood
pressure (ID 176) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
EFSA Publication; Tetens, Inge
Link to article, DOI:
10.2903/j.efsa.2011.2221
Publication date:
2011
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Publication (2011). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to folate and maintenance of normal blood pressure (ID 176) pursuant
to Article 13(1) of Regulation (EC) No 1924/2006. Parma, Italy: European Food Safety Authority.  (The EFSA
Journal; No. 2221). DOI: 10.2903/j.efsa.2011.2221
  EFSA Journal 2011;9(6):2221 
 
Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the 
substantiation of health claims related to folate and maintenance of normal blood pressure (ID 176) pursuant to Article 13(1) 
of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2221. [14 pp.]. doi:10.2903/j.efsa.2011.2221. Available online: 
www.efsa.europa.eu/efsajournal 
 
© European Food Safety Authority, 2011 
SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to folate 
and maintenance of normal blood pressure (ID 176) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to folate and maintenance of normal blood pressure. The scientific substantiation is based 
on the information provided by the Member States in the consolidated list of Article 13 health claims 
and references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claim is folate. The Panel considers that folate is 
sufficiently characterised. 
The claimed effect is “cardiovascular health”. The target population is assumed to be the general 
population. In the context of the proposed wordings, the Panel assumes that the claimed effect relates 
to the maintenance of normal blood pressure. The Panel considers that maintenance of normal blood 
pressure is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that no human intervention studies from which 
conclusions could be drawn on an effect of folate intake on blood pressure were provided, and that 
two large prospective cohort studies which addressed the association between folate intake and 
incident hypertension in women had substantial weaknesses as the incidence of hypertension was self-
reported and folate intake data (from diet and supplements) were collected by semi-quantitative food 
frequency questionnaires.  
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-963, adopted on 25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
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Working Group on Claims Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Cardiovascular Health/Oxidative Stress: Antti Aro, Marianne Geleijnse, Marina Heinonen, Ambroise Martin, Wilhelm 
Stahl and Henk van den Berg. 
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On the basis of the data presented, the Panel concludes that a cause and effects relationship has not 
been established between the dietary intake of folate and maintenance of normal blood pressure.  
KEY WORDS 
Folate, blood pressure, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 176) 
The food constituent that is the subject of the health claim is calcium L-methylfolate. 
Calcium-L-methylfolate is a synthetic folate compound used in food supplements and food 
fortification; it is synthesised by reduction of folic acid to tetrahydrofolic acid followed by 
methylation and diastereoselective crystallisation (in water) of L-methylfolate as its calcium salt.  
In the context of the references provided, the Panel assumes that the food constituent that is the 
subject of the claim is folate, which is the generic name for a number of derivatives of 
pteroylglutamic acid (PGA, folic acid). Natural (dietary) folates are mostly reduced folates, i.e. 
derivatives of tetrahydrofolate (THF) (SCF, 2000). 
Different forms of folate, including calcium-L-methylfolate, are authorised for addition to foods 
(Annex II of the Regulation (EC) No 1925/2006
6
 and Annex II of Directive 2002/46/EC
7
). This 
evaluation applies to folate naturally present in foods and those forms authorised for addition to foods 
(Annex II of the Regulation (EC) No 1925/2006 and Annex II of Directive 2002/46/EC). 
The Panel considers that the food constituent, folate, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health (ID 176) 
The claimed effect is “cardiovascular health”. The Panel assumes the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect relates to the 
maintenance of normal blood pressure. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
7 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
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Blood pressure is the pressure (force per unit area) exerted by circulating blood on the walls of blood 
vessels. Elevated blood pressure, by convention above 140 mmHg (systolic) and/or 90 mmHg 
(diastolic), may compromise the normal arterial and cardiac function. 
The Panel considers that maintenance of normal blood pressure is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 176) 
The majority of the references provided for the scientific substantiation of the claim included 
narrative reviews which did not contain original data that could be used for the scientific 
substantiation of the claim. Most of the human studies provided did not contain data on folate (or 
calcium L-methylfolate) intake, assessed the effects of folate or folic acid in combination with other 
food constituents (e.g. vitamin B6, vitamin E), or addressed health outcomes other than blood 
pressure (e.g. folate kinetics, homocysteine concentrations in relation to the risk of coronary heart 
disease and stroke, risk of cardiovascular disease, the MTHFR 677C→T polymorphism in relation to 
the risk of coronary heart disease, peripheral arterial disease, endothelial function, arterial stiffness 
and compliance, common carotid intima-media thickness, antioxidant status, markers of oxidative 
stress, insulin resistance, parameters of coronary blood circulation). The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim. 
Two double-blind, randomised, controlled, parallel group intervention studies investigated the effects 
of 5 mg folic acid daily for 3-4 weeks on blood pressure in cigarette smokers and in subjects with 
normal or high normal blood pressure (Mangoni et al., 2002; Williams et al., 2005). The Panel notes 
that these studies used daily doses of folic acid five times above the Tolerable Upper Intake Level 
(UL) for adults (1,000 g) (SCF, 2000) and more than ten times the doses proposed in the conditions 
of use for this claim (400 g). The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
Forman et al. (2005) prospectively examined the association between folate intake and risk of incident 
hypertension in two large cohorts of younger and older women who were followed for eight years. 
The study cohorts consisted of 93,803 women aged 27 to 44 years in the Nurses' Health Study II 
(1991-1999) and 62,260 older women aged 43 to 70 years in the Nurses' Health Study I (1990-1998), 
and who did not have a history of hypertension. Baseline information on dietary folate and 
supplemental folic acid intakes was derived from semi-quantitative food frequency questionnaires and 
was updated every four years. The outcome variable was relative risk of incident self-reported 
hypertension during the eight years of follow-up. After adjusting for multiple potential confounders, 
younger women who consumed at least 1,000 g/day of total folate (dietary plus supplemental intake) 
had a decreased risk of hypertension (relative risk [RR] 0.54; 95% CI = 0.45-0.66; p for trend <0.001) 
compared with those who consumed less than 200 g/day. For older women the RR was 0.82 (95% CI 
= 0.69-0.97; p for trend = 0.05) for the same comparison. The Panel notes that incident hypertension 
was self-reported, and that dietary intake data were collected by semi-quantitative food frequency 
questionnaires.  
In weighing the evidence, the Panel took into account that no human intervention studies from which 
conclusions could be drawn on an effect of folate intake on blood pressure were provided, and that 
two large prospective cohort studies which addressed the association between folate intake and 
incident hypertension in women had substantial weaknesses as the incidence of hypertension was self-
reported and folate intake data (from diet and supplements) were collected by semi-quantitative food 
frequency questionnaires.  
The Panel concludes that a cause and effects relationship has not been established between the dietary 
intake of folate and maintenance of normal blood pressure.  
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, folate, which is the subject of the health claim is sufficiently 
characterised. 
 The claimed effect is “cardiovascular health”. The target population is assumed to be the 
general population. Maintenance of normal blood pressure is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the dietary intake of folate 
and maintenance of normal blood pressure. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-963). The 
scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES  
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
8
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
9
  
Foods are commonly involved in many different functions
10
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
8 OJ L12, 18/01/2007 
9 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
10 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Folate and maintenance of normal blood pressure 
 
10 EFSA Journal 2010;9(6):2221 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
Folate and maintenance of normal blood pressure 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to folate, including conditions of use from similar claims, as 
proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
176 Calcium L-methylfolate 
(syn.: L-5-methyltetra-
hydrofolic acid, calcium 
salt; Vitamin B9), 
MetafolinTM 
 
Cardiovascular health 
 
Helps keep arteries/blood vessels 
healthy; 
Contributes to healthy arteries/ blood 
vessels; 
Supports heart health by contributing 
to the normal functioning of the 
arteries/blood vessels; 
Helps maintain a normal blood 
pressure by supporting the elasticity 
of blood vessels/arteries. 
Conditions of use 
- ≥ 400 µg/d 
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GLOSSARY AND ABBREVIATIONS 
CI   Confidence interval 
MTHFR  Methylene tetrahydrofolate reductase 
PGA   Pteroylglutamic acid 
RR   Relative risk 
THF   Tetrahydrofolate  
UL   Tolerable Upper Intake Level  
